<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>anti-PD-1 antibodies &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/anti-pd-1-antibodies/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Thu, 08 Oct 2026 12:09:09 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>anti-PD-1 antibodies &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Under the Microscope: Tumor Invasion Grading Predicts Survival After Liver Cancer Conversion Therapy</title>
		<link>https://bioengineer.org/under-the-microscope-tumor-invasion-grading-predicts-survival-after-liver-cancer-conversion-therapy/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Thu, 08 Oct 2026 12:09:09 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[anti-PD-1 antibodies]]></category>
		<category><![CDATA[conversion therapy]]></category>
		<category><![CDATA[hepatectomy]]></category>
		<category><![CDATA[Hepatocellular Carcinoma]]></category>
		<category><![CDATA[immunotherapy]]></category>
		<category><![CDATA[liver cancer]]></category>
		<category><![CDATA[microvascular invasion]]></category>
		<category><![CDATA[overall survival]]></category>
		<category><![CDATA[prognosis]]></category>
		<category><![CDATA[recurrence-free survival]]></category>
		<category><![CDATA[risk stratification]]></category>
		<category><![CDATA[tyrosine kinase inhibitors]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=407361</guid>

					<description><![CDATA[A multicenter study shows that grading the severity of microvascular invasion in resected liver tumors strongly predicts recurrence and survival in patients whose initially unresectable hepatocellular carcinoma was converted to operable disease with tyrosine kinase inhibitors and anti-PD-1 antibodies.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">407361</post-id>	</item>
	</channel>
</rss>
